Santiago Viteri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Santiago Viteri has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Benjamin Cortot
CNRS, Inserm, Institut Pasteur de Lille, UMR9020‐UMR1277‐Canther‐Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille CHU Lille Lille France
23 shared publications - Byoung Chul Cho
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
23 shared publications Christian Britschgi
23 shared publications- Christine M. Bestvina
Department of Medicine, Section of Hematology Oncology, Thoracic Oncology Program, The University of Chicago, Chicago, USA
23 shared publications Egbert F. Smit
23 shared publicationsElif Sikoglu
23 shared publications
Latest Publications
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary file S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
TCR Clone lists identified in post-treatment samples
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary file S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
TCR Clone lists identified in post-treatment samples
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table S5 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Table S5: Gene Ontology enrichment analysis of differentially expressed genes between High and Low Top 1% clonal space tumors.
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table S5 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Table S5: Gene Ontology enrichment analysis of differentially expressed genes between High and Low Top 1% clonal space tumors.
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
PFS and OS survival stratified by pre-treatment evenness, TMB, and PD-L1. Correlation between tissue evenness and TMB or PD-L1. Mutations and pre-treatment tissue top 1% clonal space.
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
PFS and OS survival stratified by pre-treatment evenness, TMB, and PD-L1. Correlation between tissue evenness and TMB or PD-L1. Mutations and pre-treatment tissue top 1% clonal space.
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Tissue TCR evenness and top 1% clonal space are independent of reported read counts, clones identified, and tissue origing.
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Tissue TCR evenness and top 1% clonal space are independent of reported read counts, clones identified, and tissue origing.
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Clonal space occupied by shared or newly emergent clones top 1% post-T clones in PBMCs at pre- and post-treatment timepoints.
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Clonal space occupied by shared or newly emergent clones top 1% post-T clones in PBMCs at pre- and post-treatment timepoints.
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table S1, S2, and S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Table S1: Patients' samples and techniques. Table S2: Summary of available samples. Table S3: Canonical somatic tumor mutations and top 1%.
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table S1, S2, and S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Table S1: Patients' samples and techniques. Table S2: Summary of available samples. Table S3: Canonical somatic tumor mutations and top 1%.
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Stability of evenness and top 1% across technical replicates and Clonal reproducibility
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Stability of evenness and top 1% across technical replicates and Clonal reproducibility
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Table S4: Differentially expressed genes between High and Low Top 1% clonal space tumors.
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table S4 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Table S4: Differentially expressed genes between High and Low Top 1% clonal space tumors.
- Open Access
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary file S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
TCR Clone lists identified in pre-treatment samples
- 8 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary file S1 from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
TCR Clone lists identified in pre-treatment samples